03.01.08
Israel-based Enzymotec says it has received “No Questions” from the FDA regarding its GRAS notification on Sharp-PSTM (phosphatidylserine). Enzymotec expects to publish the results of three human clinical trials on phosphatidylserine (PS) in the next few months. “We believe that PS can expand into functional foods in the near future and a GRAS determination was the first step to enable that,” said Iris Meiri-Benedek, Enzymotec regulatory affairs manager. “We have already tested its applicability into chocolate bars and dairy applications with great feedback on taste and texture.”